Request Demo
CAGE Bio Announces Collaboration to Advance First-in-Class Treatments for Cutaneous Graft versus Host Disease
27 Aug 2025
SAN CARLOS, Calif. and DALLAS, Aug. 27, 2025 /PRNewswire/ -- CAGE Bio Inc., a leader in advancing innovative therapies for targeted and localized treatment of immunological skin diseases, today announced it has entered into a collaboration with Mayo Clinic to develop novel therapeutics aimed at addressing unmet needs of patients with chronic graft-versus-host disease (GvHD).
Under this agreement, CAGE Bio and Mayo Clinic will focus on cutaneous GvHD, a debilitating condition that remains difficult to manage with potential adverse effects, impacting patients' quality of life*. The collaboration will combine Mayo Clinic's clinical expertise with CAGE Bio's proprietary ionic liquid technology to accelerate development of new treatment options.
"This engagement strengthens our innovative pipeline," said Dr. Nitin Joshi, Chief Executive Officer, CAGE Bio. "We are thrilled to collaborate with Mayo Clinic to jointly address significant unmet needs for patients with debilitating dermatological conditions. This collaboration highlights the value of CAGE Bio's ionic liquid technology for developing critical therapies for patients."
About CAGE Bio Inc.
CAGE Bio Inc. is a biotechnology company dedicated to developing innovative therapies for immune-mediated diseases using its proprietary ionic liquid technology platform. The company's pipeline includes clinical and preclinical assets targeting high incidence dermatological conditions.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.
* https://www.astctjournal.org/article/S2666-6367(21)00950-7/fulltext
www.CAGEBio.com
SOURCE CAGE Bio Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!